In human genome, only 1−2% of the DNA sequences encode for protein, yet 70−80% are transcribed into RNA. Therefore, the regulation of the RNAs production or destruction provided a new approach to study the cell function and investigate the future therapeutics. In the past decade, several posttranscriptional RNA-regulating technologies have been developed by molecular biologists, including RNAi, artificial RNases, RNA-binding PARPs. Recently, ribonuclease targeting chimeras (RIBOTACs), a novel technology originated from antiviral innate immune system of 2-5A/RNase L, have been emerging as an important tools to selective degradation of RNAs. In human cells, the 2’,5’-oligoadenylates synthetase (OAS) will synthesize 2’,5’-oligoadenylates (2-5A), responding to viral infections, and then dimerize and activate RNase L, an endogenous ribonuclease, which results in cleavage of all RNA in the cell. The RIBOTACs applied a small-molecule-conjugated 2-5A for targeting specific RNA and restricting its nuclease activity on the target.
Based on RIBOTACs, the Sequence-specific RNA Repression (SERRE) technology platform has been developed by BOC Sciences. Our research staff modified the structure of ribonuclease recruiting moiety for better efficiency and stability in vivo, and significantly improved the RNA selectivity by conjugation of PNA or other sequence-specific molecules.
Why choose BOC Sciences?
The BOC Sciences’s SERRE platform will greatly facilitate your research on RNA regulation and drug discovery. Our experienced staff of BOC Sciences SERRE Platform will assist your drug discovery. For further research, our cellular platform and mouse platform will help you with the experimental solutions on cellular RNA detection, RT-qPCR, cell apoptosis, toxicity, tumor xenograft model and IVBI pharmacodynamics study in vivo. We would be glad to hear from you and we’re looking forward to providing the best solution for you.